← Leaderboards
Ravi Madan
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateImmunotherapyImmuneImmune ResponseRecurrenceEvaluationCancer PatientImmunologicsCollaborationsSafetyToxic EffectCancer VaccinesClinical TrialsImageCastration Resistant Prostate CancerBiochemicalFollow-UpBaseRadiationProgression-Free SurvivalsProstateAndrogen AntagonistsDocetaxelChemotherapy
Grant awards (31)
Evaluation of novel treatments in biochemically recurrent prostate$668,924
ZIA · FY2025 · CA · contact PI
Defining Roles for PSMA PET Imaging in Prostate Cancer$501,693
ZIA · FY2025 · CA · contact PI
Evaluation of Immune-based Combinations in Prostate Cancer$501,693
ZIA · FY2025 · CA · contact PI
Evaluation of novel treatments in biochemically recurrent prostate$556,986
ZIA · FY2024 · CA · contact PI
Defining Roles for PSMA PET Imaging in Prostate Cancer$417,740
ZIA · FY2024 · CA · contact PI
Evaluation of Immune-based Combinations in Prostate Cancer$417,740
ZIA · FY2024 · CA · contact PI
Evaluation of Immune-based Combinations in Prostate Cancer$485,739
ZIA · FY2023 · CA · contact PI
Natural History of Biochemically Recurrent Prostate Cancer$364,304
ZIA · FY2023 · CA · contact PI
Evaluation of novel treatments in biochemically recurrent prostate$364,304
ZIA · FY2023 · CA · contact PI
Evaluation of novel treatments in biochemically recurrent prostate$616,806
ZIA · FY2022 · CA · contact PI
Evaluation of Immune-based Combinations in Prostate Cancer$493,445
ZIA · FY2022 · CA · contact PI
Natural History of Biochemically Recurrent Prostate Cancer$123,362
ZIA · FY2022 · CA · contact PI
Evaluation of immunotherapy-novel treatments in biochemically recurrent prostate$502,778
ZIA · FY2021 · CA · contact PI
Evaluation of Immune-based Combinations in Metastatic Prostate Cancer$402,223
ZIA · FY2021 · CA · contact PI
Development of Immunotherapy for Medullary Thyroid Cancer$50,278
ZIA · FY2021 · CA · contact PI
Novel Anti-androgen strategies in Prostate Cancer$50,278
ZIA · FY2021 · CA · contact PI
Evaluation of immunotherapy-novel treatments in biochemically recurrent prostate$500,512
ZIA · FY2020 · CA · contact PI
Evaluation of Immune-based Combinations in Metastatic Prostate Cancer$364,008
ZIA · FY2020 · CA · contact PI
Development of Immunotherapy for Medullary Thyroid Cancer$45,500
ZIA · FY2020 · CA · contact PI
Evaluation of Immune-based Combinations in Metastatic Prostate Cancer$429,279
ZIA · FY2019 · CA · contact PI
Evaluation of immunotherapy-novel treatments in biochemically recurrent prostate$343,422
ZIA · FY2019 · CA · contact PI
Development of Immunotherapy for Medullary Thyroid Cancer$85,856
ZIA · FY2019 · CA · contact PI
Combination therapies involving novel cancer vaccines$125,846
ZIA · FY2013 · CA · contact PI
Combination Studies in Prostat Cancer$75,508
ZIA · FY2013 · CA · contact PI
Cancer Therapy Trials using novel vaccine platforms$50,338
ZIA · FY2013 · CA · contact PI
Combination therapies involving novel cancer vaccines$161,730
ZIA · FY2012 · CA · contact PI
Cancer Therapy Trials using novel vaccine platforms$161,730
ZIA · FY2012 · CA · contact PI
Combination therapies involving novel cancer vaccines$15,827
ZIA · FY2011 · CA · contact PI
Cancer Therapy Trials using novel vaccine platforms$15,827
ZIA · FY2011 · CA · contact PI
Combination therapies involving novel cancer vaccines$114,971
ZIA · FY2010 · CA · contact PI
Cancer Therapy Trials using novel vaccine platforms$114,971
ZIA · FY2010 · CA · contact PI